Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Cash & Equivalents (2018 - 2022)

NovaBridge Biosciences (NBP) has disclosed Cash & Equivalents for 5 consecutive years, with $451.9 million as the latest value for Q4 2022.

  • Quarterly Cash & Equivalents fell 18.0% to $451.9 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $451.9 million through Dec 2022, down 18.0% year-over-year, with the annual reading at $342.9 million for FY2022, 37.98% down from the prior year.
  • Cash & Equivalents for Q4 2022 was $451.9 million at NovaBridge Biosciences, down from $551.1 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $718.1 million in Q4 2020, with the low at $161.4 million in Q4 2019.
  • Average Cash & Equivalents over 5 years is $422.4 million, with a median of $451.9 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents fell 29.74% in 2019, then surged 344.94% in 2020.
  • Over 5 years, Cash & Equivalents stood at $229.7 million in 2018, then dropped by 29.74% to $161.4 million in 2019, then soared by 344.94% to $718.1 million in 2020, then dropped by 23.25% to $551.1 million in 2021, then dropped by 18.0% to $451.9 million in 2022.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $451.9 million, $551.1 million, and $718.1 million for Q4 2022, Q4 2021, and Q4 2020 respectively.